Company Overview of NovaCardia, Inc.
NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company develops KW-3902, an adenosine A1 receptor antagonist, which is in Phase III clinical trials for the treatment of the acute form of congestive heart failure in patients with renal impairment and fluid overload. It also develops an oral formulation of KW-3902 for the treatment of chronic congestive heart failure. In addition, the company develops K201 (JTV-519) for the treatment of atrial fibrillation, an irregular heartbeat. The company was founded in 2001 and is headquartered in San Diego, California. As of September 11, 2007, NovaCardia, Inc. operates as a subsidiary of Merck & Co. Inc.
12750 High Bluff Drive
San Diego, CA 92130
Founded in 2001
Key Executives for NovaCardia, Inc.
NovaCardia, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|Lycera Corp.||United States|
|QPS, L.L.C.||United States|
|Cargill Health & Food Technologies||United States|
|DemeRx, Inc.||United States|
|HMGene, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact NovaCardia, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.